PRE-EXPOSURE PROPHYLAXIS OF HIV INFECTION

This study tested two ways to prevent HIV in over 5,000 adolescent girls and young women at risk of infection. One group received a twice-yearly injection of lenacapavir, while another took a daily pill (emtricitabine/tenofovir alafenamide). The goal was to see how well each meth…

This study looks at a new HIV prevention option for cisgender women in the US: a shot given under the skin every 6 months, called lenacapavir. Researchers want to see how the drug behaves in the body, how safe it is, and if women find it acceptable compared to taking a daily pill…

This study tested a long-acting shot called lenacapavir, given every 6 months, to prevent HIV infection. Over 3,200 participants (cisgender men, transgender women, transgender men, and gender nonbinary people) who were at risk of HIV took part. The results showed that lenacapavir…

This study looks at a new long-acting shot called lenacapavir, given every 6 months, to prevent HIV in people who inject drugs. About 181 participants in the US will receive either the shot or daily pills, and researchers will check how the drug moves through the body and if it i…

This study tests a new HIV prevention method: a shot called lenacapavir given only twice a year. It compares how well people stick with this shot versus taking a daily pill (Truvada). The study involves 268 people at higher risk of HIV, including men who have sex with men, transg…